Advaxis Announces Promotion of Dr. Robert Petit and Daniel J. O'Connor
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the Board of Directors of Advaxis has elected Dr. Robert Petit, currently Vice President of Clinical Operations and Medical Affairs, to the position of Chief Scientific Officer. The Board has also elected Daniel J. O'Connor, currently Senior Vice President, Chief Legal and Business Development Officer, to Executive Vice President. Promotions were made effective May 3, 2013.
"The excellent contributions Robert and Dan have made to Advaxis have led to the Board's decision to elevate their status within the company"
"The excellent contributions Robert and Dan have made to Advaxis have led to the Board's decision to elevate their status within the company," commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis. "We look forward to working with our skilled and highly experienced leadership team during the next stage of development at Advaxis."
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is being evaluated in 5 clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
Contacts
Advaxis, Inc.
Diana Moore
Director, Investor Relations & Business Development
609-452-9814
[email protected]